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ABSTRACT 
The increasing burden of stroke and dementia emphasises the need for new, well-tolerated 
and cost-effective primary prevention strategies that can reduce the risks of stroke and 
dementia worldwide, and specifically in low and middle-income countries (LMICs). 
This paper outlines conceptual frameworks of three primary stroke prevention strategies: (a) 
the ‘polypill’ strategy; (b) a ‘population-wide’ strategy; and (c) a ‘motivational population-wide‘ 
strategy. 
a) A polypill containing generic low-dose ingredients of blood pressure and lipid lowering 
medications (e.g. candesartan 16 mg, amlodipine 2.5 mg and rosuvastatin 10 mg) seems a 
safe and cost-effective approach for primary prevention of stroke and dementia. 
b) A population-wide strategy reducing cardiovascular risk factors in the whole population, 
regardless of the level of risk is the most effective primary prevention strategy. A motivational 
population-wide strategy for the modification of health behaviours (e.g. smoking, diet, physical 
activity) should be based on the principles of cognitive behavioural therapy. Mobile 
technologies, such as smartphones, offer an ideal interface for behavioural interventions (e.g. 
Stroke Riskometer app) even in LMICs.  
c) Community health workers (CHWs) can improve the maintenance of lifestyle changes as 
well as the adherence to medication, especially in resource poor areas. An adequate training 
of CHWs is a key point. 
Conclusion: An effective primary stroke prevention strategy on a global scale should integrate 
pharmacological (polypill) and lifestyle modifications (motivational population-wide strategy) 
interventions. Side effects of such an integrative approach are expected to be minimal and the 
benefits among individuals at low-to-moderate risk of stroke could be significant. In the future 
pragmatic field trials will provide more evidence. 
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Stroke and dementia/cognitive impairment are the second most common causes of death and 
disability in the world.1-4 In 2016, there were approximately 124 million people living with stroke 
and dementia worldwide, and every year stroke and dementia affect about 13.7 million and 7.8 
million people, respectively.1,2 The commonest outcome of cerebrovascular disease is not 
stroke, but cognitive impairment.5 Given the reciprocal links and shared risk factors between 
cerebrovascular disease and dementia, interventions to prevent stroke should be beneficial 
to prevent dementia.6 Over the last three decades stroke incidence and mortality rates in the 
world have decreased, however the absolute number of people affected by stroke, died from 
or remained disabled from stroke as well as the absolute number of people with dementia 
has increased in all countries of the world.1,2 Moreover, globally since 2010 there has been 
an increase in stroke and dementia mortality and disability-adjusted life-years lost (DALYs) 
and stroke has become a disease primarily of  working-age people (almost 60% of people 
affected by stroke in 2016 were people under 70 years of age) and since 1990 there has 
been a large and ongoing increase in stroke incidence rates in people aged 15 to 49 years.3  
The increased burden of stroke and dementia across all countries in the world provides strong 
evidence that currently used primary stroke and dementia prevention strategies are not 
sufficiently effective.7 These inefficiencies are further highlighted by the significant sex and 
ethnic disparities in stroke8 and globally observed increases in the prevalence of many risk 
factors (including type 2 diabetes mellitus and various lifestyle factors).7,9 Due to ongoing 
ageing of the population, population growth and a trend towards increasing prevalence of 
many important risk factors for stroke and dementia, the burden of stroke and dementia is 
likely to continue to increase1,2 unless cost-effective primary stroke/dementia preventative 
strategies are found and implemented.7,9 
The huge and increasing burden of stroke, dementia and other non-communicable diseases 
(NCDs) has led to the historical 2011 United Nations resolution10 followed by the WHO 
Global Action plan11 calling upon all governments to give primary prevention of non-
communicable diseases, including stroke and dementia, the highest priority. Mandatory and 
voluntary global targets were set, up to the year 2030, but the progress to date is 
unsatisfactory.12 There is a pressing need to identify new, well-tolerated and affordable 
strategies for the majority of people that will reliably reduce the risks of stroke and 
dementia/cognitive decline across all countries in the world.9,13 This paper outlines conceptual 
frameworks of three promising primary stroke prevention strategies to be pragmatically 
tested in large field trials: (a) the ‘polypill’ strategy; (b) a ‘population-wide’ strategy; and (c) a 
‘motivational population-wide” strategy. 
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Polypill strategy 
A polypill strategy for primary prevention of cardiovascular disease (CVD) was first 
introduced by Drs Wald and Law in 2003 to reduce CVD by more than 80%.14 In previous 
polypill RCTs primarily for secondary CVD prevention, this approach has yielded largely 
improved adherence to the medications (compared to usual multi-pill approach) as well as 
sizeable reductions in SBP (between 9.9 and 17.9 mmHg reduction) and low-density 
lipoprotein cholesterol (LDL-cholesterol)15,16 but caused haemorrhagic side effects in about 1 
in 6 people due to the presence of aspirin as part of the polypill.15,17 In addition, cost-
effectiveness analysis showed that most health gain in such polypill trials is achieved by the 
polypill without aspirin and a statin dose corresponding to the recommended standard 
dose.18 To maximize the treatment effect on stroke prevention while reducing the possibility of 
adverse effects, it seems reasonable for the new polypill to contain the following generic low-
dose ingredients: candesartan 16 mg, amlodipine 2.5 mg and rosuvastatin 10 mg. There is 
evidence from the large STELLAR trial that lipid-lowering effects of rosuvastatin 10 mg are 
comparable to the effects of simvastatin 80 mg, atorvastatin 40 mg, and superior to 40 mg of 
pravastatin.19 Elevated blood pressure and dyslipidaemia are well-established risk factors for 
stroke and dementia (including cognitive impairment).3,20,21 In the recent HOPE-3 trial, a 
combination of rosuvastatin (10 mg per day), candesartan (16 mg per day), and 
hydrochlorothiazide (12.5 mg per day) reduced CVD events by 29% over 5.6 years in adults 
at moderate risk of CVD.22 Due to well-known side effects of hydrochlorothiazide23,24 such as 
hyponatremia, hypokalemia and dysglycemia, it seems reasonable to replace it with a calcium 
channel blocker (e.g. amlodipine 2.5 mg). It was shown that calcium channel blockers not only 
reduce blood pressure level but also reduce the risk of dementia25 and blood pressure 
variability,26 a well-known independent risk factor for stroke.27 A combination of amlodipine 
with an angiotensin II receptor blocker (e.g. candesartan) was shown to be particularly 
beneficial in reducing CVD events.28 The increased risk of CVD, including stroke, is not 
restricted to those with “hypertension” or “hypercholesterolemia”, but is continuous down to 
at least a blood pressure of 115/75mmHg and total cholesterol level of 135 mg/dL (4.0 
mmol/l).29,30 There is now clear evidence that blood pressure lowering medications and statins 
reduce the risk of stroke and cognitive decline.20,31-35 The use of a combination of blood 
pressure and lipid lowering medications is proven to be generally safe even in people with 
average or below-average systolic blood pressure and cholesterol levels36 and, in low dosages 
such as in the polypill, as an adjunct therapy to other blood pressure and lipid lowering 
medications.37,38 However, there is considerable uncertainty about whether these benefits 
extend to primary prevention among people without or with borderline hypertension or 
dyslipidaemia. In addition, it has been argued that prescribing a single pill, without lifestyle 
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changes, to prevent CVD is pointless and could lead to excessive medicalisation39 and 
neglection of lifestyle risk factors.40 
 
Population-wide strategy 
A population-wide strategy for primary prevention of CVD was first introduced by Geoffrey 
Rose in 1981.41 By reducing exposure to CVD risk factors (such as smoking cessation, salt 
and sugar reduction, physical inactivity etc.) in the whole population, regardless of the level 
of CVD risk, this is undoubtedly the most effective primary prevention strategy not only for 
stroke and dementia but also for other NDCs that share common risk factors. The WHO has 
recommended that governments consider the implementation of the “WHO best buy” 
interventions42 that include some evidence-based, cost-effective, feasible population-wide 
primary stroke prevention interventions. Despite these recommendations, opposition from 
industry and the requirements for legislative/regulatory changes have made this strategy 
very challenging to implement on a national level,7 especially in LMIC.43 A recently 
introduced WHO technical package for CVD management in primary health care via team-
based care and healthy-lifestyle counselling44 offers an opportunity to enhance primary 
stroke, dementia and CVD prevention strategy in community low-resource settings. 
 
Motivational population-wide strategy 
A motivational population-wide strategy for primary stroke prevention was first introduced by 
Feigin and Norrving in 2014.45 Lifestyle risk factors, such as poor diet, low physical activity, 
overweight and smoking, account for over 70% of the stroke burden worldwide.3 Importantly, 
there is evidence that modifying unhealthy behaviours (e.g. smoking, poor diet, physical 
inactivity) is feasible, improves health outcomes, and also reduces stroke, cognitive decline 
and dementia risk and healthcare costs.20,31,46-48 The critical identified elements of effective 
behavioural interventions are based on principles of cognitive behavioural therapy, including 
behavioural motivation, goal-setting and empowering.44 However, to be widely available such 
interventions must be affordable and easily accessible. Widely used mobile technologies, such 
as smartphones, offer an ideal interface for behavioural interventions to the majority of people, 
even in low and middle-income countries (LMICs). AUT University has developed49 and 
validated50 the novel, not-for-profit Stroke Riskometer app. It uses individual data on 
demographic, health and lifestyle factors to derive a person’s validated absolute and relative 
risk of stroke.49,50 The app then provides, saves and tracks an individual’s risk self-
management information (with goal-setting options and push notifications as a prompt to users 
to take action to achieve their goals), thereby empowering users to act on this potentially life-
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saving information. This provides an opportunity to combine both population-wide and high-
risk prevention strategies, thus opening up a new paradigm for primary prevention of stroke, 
dementia and other major NCDs.13,45 Data from the recent pilot RCT on Stroke Riskometer app 
indicate motivational value and potential efficacy of this novel mobile intervention to improve 
lifestyle risk factors as well as acceptability of this lifestyle intervention.51,52 
Smartphone apps can serve as an educational tool to assess the CVD risk, improve health 
education, and modify lifestyle behaviours. Unfortunately, the adherence to healthy 
behaviour is often poor. The involvement of community health workers (CHWs) can be an 
additional powerful opportunity to advance primary stroke prevention strategies, especially in 
resource poor areas, by increasing recruitment, minimizing drop-outs, and by improving the 
maintenance of lifestyle changes as well as the adherence to medications.  
CHWs are trained individuals embedded in the community with limited or no formal medical 
education who provide a broad range of patient oriented health services. Their main roles in 
primary care are clinical services, community and social resource connections, and health 
education and coaching.53 By sharing life experiences, culture, ethnicity, language and 
socio-economic status, they can provide peer support and more effectively link communities 
to the health and social services systems.53-55 Despite the heterogeneity of CHW programs 
and the often-low quality of studies, there is growing evidence that CHWs can improve 
health outcomes.55-58 Programmes involving CHWs have shown to be particularly successful 
to reduce inequities in access to health care in settings with shortage of health 
professionals.53,55,58 Factors central to effective CHWs programs were community 
embeddedness, supportive supervision, continuous education, and adequate logistical 
support and supplies.55  
While the majority of programs involving CHWs focus on maternal-child health and HIV, a 
number of studies showed that CHWs can successfully play a role in primary prevention 
programs for NCDs.56 Compared to standard care CHWs programmes for NCDs prevention 
in LMICs were successful to increase smoking cessation and decrease blood pressure and 
blood sugar levels.56 Similarly, community-based primary prevention programs to improve 
cardio-metabolic risk in non-urban communities were more effective than non-community 
based programs in improving blood pressure, BMI and lipids.57 Furthermore, a review of 9 
studies showed that interventions involving CHWs for CVD prevention were also cost 
effective.59 However, no trial has addressed CHWs for the primary prevention of stroke and 
dementia/cognitive decline. 
An adequate training is a key point to empower CHWs to fulfil their role; this training should 
include technical competency as well as social skills.55 This training for stroke prevention 
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and cognitive decline could be based on the HEARTS technical package for cardiovascular 
disease management in primary health care which includes a module with practical material 
and strategies for primary health care trainers on healthy-lifestyle counselling.44  
 
Integrative approach 
For a primary prevention strategy targeted at stroke and dementia to be most effective on a 
global scale it should include both pharmacological (such as a polypill containing blood 
pressure and lipid lowering medications) and lifestyle modification (such as motivational 
population-wide strategies) interventions.7,60 Ideally, any primary stroke and dementia 
prevention interventions should include a population-wide strategy for primary prevention of 
CVD (such as the “WHO best buy” interventions),42 which could be enhanced by the WHO 
technical package for CVD management in primary health care.44 In 2015, the World Stroke 
Organization, Alzheimer's Disease International, the Alzheimer's Society UK, Public Health 
England, the American Heart/Stroke Association, the Alzheimer's Association, and 16 other 
international, regional, and national organizations  endorsed a proclamation on stroke and 
potentially preventable dementias, calling for their joint prevention.61 
There is evidence of a reduced risk of stroke and mild cognitive impairment following 
reductions in blood pressure62,63 and cholesterol64,65 and lifestyle modifications,31,66-68 
including eHealth interventions69,70 in middle-aged individuals (i.e., those aged 50 to 70) at 
high risk of CVD. Collectively, existing data provide evidence that the new polypill (a three-
component pill containing candesartan 16 mg, amlodipine 2.5 mg and rosuvastatin 10 mg) 
with lifestyle modification via the Stroke Riskometer app may provide a more effective means 
to prevent stroke than either approach individually (Figure). Its applicability across a large and 
varied population will also enhance generalizability.71 These interventions also have the 
potential to reduce the risks of other major non-communicable diseases (NCDs), including 
cognitive decline, ischemic heart disease and type 2 diabetes mellitus. 
 
Expected global impact and future directions “cut stroke in half” 
The net benefits of combined treatment with blood pressure lowering, statin and lifestyle 
modification could be substantial, since each intervention can work in an independent and 
additive manner. The potential impact of controlling risk factors for the burden of stroke and 
cognitive decline is substantial, as it has also been estimated that about 90% of stroke is 
attributable to ten modifiable risk factors including hypertension, obesity, hyperlipidaemia, 
smoking and diabetes,3,8 and it has been estimated that about 35% of dementia is 
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attributable to a combination of nine modifiable risk factors including midlife hypertension 
and obesity, later life smoking, physical inactivity, and diabetes.20 Based on extrapolation 
from previous trials, a more than halving of cardiovascular risk (including stroke) would be 
expected. This is likely to exceed a two-thirds reduction after the first two years, once the full 
effects of the component medications and lifestyle modification accrue. Moreover, these 
treatments are generally affordable (estimated at a dollar a week) and safe given the low-
dose combinations of blood pressure lowering agents and statins. Adverse effects are 
expected to be minimal and would be vastly outweighed by the net benefits among 
individuals at low-to-moderate risk of stroke and dementia. In the absence of robust 
evidence for the benefits, safety, and cost-effectiveness of this approach, large randomized 
controlled trials with clinically meaningful endpoints demonstrating efficacy for the reduction 
of stroke and dementia are urgently required.72,73 
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Box: Actions for Primary Prevention in Stroke 
• Given the immense and increasing burden of stroke and dementia - especially in low- to 
middle-income countries (LMIC) - cost-effective primary stroke preventative 
strategies have to be found and implemented worldwide. Such strategies may include 
population-specific prevention or governmental-based strategies (e.g. via taxation) that 
address unhealthy behavior.  
• Risk factor interventions and medications have to be affordable and easily accessible 
• Given the reciprocal links between cerebrovascular disease and dementia, 
interventions to prevent stroke should go hand-in-hand with interventions to prevent 
dementia 
• A population-wide strategy, independent of stroke risk, is the most effective primary 
prevention strategy and does also target other non-communicable diseases that share 
common risk factors with stroke. 
• A polypill strategy containing generic low-dose ingredients of blood pressure lowering 
medications and statins to reduce the risk of stroke and cognitive decline (e.g. 
candesartan 16 mg, amlodipine 2.5 mg and rosuvastatin calcium 10 mg) is a safe 
approach to improve adherence to medications and has been shown to lower systolic 
blood pressure as well as low-density lipoprotein cholesterol. 
• A motivational population-wide strategy should target modification of lifestyle (poor diet, 
smoking, physical activity). Critical elements of effective behavioral interventions are 
based on principles of cognitive behavioral therapy, including behavioral motivation, goal-
setting and empowering. Education should include self-efficacy, basic understanding of 
stroke, its risk factors and measures required for prevention. Interventions have to be 
population-specific and culturally adapted. 
• Mobile health technologies (e.g. smartphone apps), electronic health tools and social 
media should be included for risk factors screening and serve as interface for behavioral 
interventions because they are accessible to the majority of people, even in LMICs. 
• Community health workers should be involved as link between communities and the 
health and social services systems. Especially in resource poor areas they can reduce 
inequities in access to health care and serve as peer support thereby improving lifestyle 
changes, adherence to medication as well as health outcomes. The WHO technical 
package for CVD management in primary health care offers practical tools for team-
based care and teaching material for trainers in healthy-lifestyle counselling. 
• Clinical field trials including an initiative for a large randomized controlled trial have to 
be carried out to test the efficacy and cost-effectiveness of an integrative approach of 
these primary prevention strategies.  
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Figure. Multi-level interventions of community health workers, polypill, and e-Health 
applications to reduce stroke incidence by 50%. 
 
 
